Safe dosages of lidocaine for facial analgesia.
Abstract
A prospective study of serum lidocaine levels in cosmetic facial surgery patients was undertaken. The findings challenge the currently accepted minimal lethal dose (MLD) for lidocaine. Complete simultaneous facial analgesia (CSFA) was accomplished in an average of 15 minutes and the recommended dosage of lidocaine was exceeded by a mean of 52.8%. This study establishes a possible basis for redefining the maximum safe dosage for lidocaine in human subjects.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 약물 | lidocaine
|
리도카인 | dict | 5 | |
| 해부 | serum lidocaine
|
scispacy | 1 | ||
| 약물 | CSFA
→ Complete simultaneous facial analgesia
|
scispacy | 1 | ||
| 질환 | MLD
→ minimal lethal dose
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | human
|
scispacy | 1 |
MeSH Terms
Anesthesia, Local; Face; Humans; Lidocaine; Maximum Allowable Concentration; Monitoring, Intraoperative; Prospective Studies; Surgery, Plastic
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative effects of pharmacological interventions in the prophylactic treatment of tension-type headache: systematic review and network meta-analysis.
- Clinical safety of a low-modification hyaluronic acid filler (MoD 2%) for facial rejuvenation.
- Fat harvesting protocol for enhanced stem cell viability - pilot study.
- Medical management of refractory trigeminal neuralgia.